• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Shares of dialysis stocks are trading higher in reaction to Novo Nordisk's Ozempic kidney disease data.

    3/5/24 10:17:05 AM ET
    $BAX
    $DVA
    $FMS
    $OM
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $BAX alert in real time by email
    Shares of dialysis stocks are trading higher in reaction to Novo Nordisk's Ozempic kidney disease data.
    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX
    $DVA
    $FMS
    $OM

    CompanyDatePrice TargetRatingAnalyst
    Fresenius Medical Care AG
    $FMS
    1/20/2026Buy → Neutral
    Goldman
    Baxter International Inc.
    $BAX
    10/31/2025Buy → Hold
    Argus
    Fresenius Medical Care AG
    $FMS
    10/15/2025Neutral → Underperform
    BofA Securities
    Fresenius Medical Care AG
    $FMS
    9/2/2025Neutral → Sell
    UBS
    Baxter International Inc.
    $BAX
    8/4/2025$25.00Buy → Hold
    Stifel
    Baxter International Inc.
    $BAX
    8/1/2025$25.00Buy → Neutral
    Goldman
    Baxter International Inc.
    $BAX
    2/26/2025$42.00Buy
    Goldman
    Baxter International Inc.
    $BAX
    2/24/2025Hold → Buy
    Argus
    More analyst ratings

    $BAX
    $DVA
    $FMS
    $OM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fresenius Medical downgraded by Goldman

    Goldman downgraded Fresenius Medical from Buy to Neutral

    1/20/26 9:08:47 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Fresenius Medical downgraded by BofA Securities

    BofA Securities downgraded Fresenius Medical from Neutral to Underperform

    10/15/25 8:35:43 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Foster Julie

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    4/9/26 4:14:45 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Wallace Steven P.

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    4/9/26 4:06:31 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Teaff James

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    4/9/26 4:05:34 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    SEC Filings

    View All

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    4/14/26 6:00:30 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.

    SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    3/27/26 11:19:26 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.

    SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)

    3/26/26 5:39:34 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

    DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co

    4/20/26 2:06:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026

    Highlights include the AAT XR, the next-generation version of the Allen Advance Table designed to support surgical teams across a range of spine procedures, and the Dynamo Series smart stretcher Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents, at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo, taking place April 11-14, 2026 in New Orleans. New offerings include the AAT XR spine surgical table and the Dynamo Series smart stretcher, both on display

    4/13/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everyw

    4/8/26 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Names Derick Elliott as Executive Vice President of Commercial

    SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately. Mr. Elliott is responsible for Outset's commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He joins Outset with more than 30 years of sales and marketing experience from Stryker, Cardinal Health and most recently SpendMend, a private company where he successfully drove a comm

    4/6/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

    Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F

    12/10/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $BAX
    $DVA
    $FMS
    $OM
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

    DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co

    4/20/26 2:06:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everyw

    4/8/26 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

    Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

    2/24/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care